QIAGEN concludes strategic alternatives review

03-Jan-2020 - Netherlands

Qiagen N.V. announced that it has concluded the previously announced review of potential strategic alternatives, and has determined the execution of its current stand-alone business plan represents the best opportunity to drive future value creation.

The Supervisory Board and Management Board of QIAGEN, in accordance with their fiduciary duties and in consultation with their financial and legal advisors, held discussions with interested parties to explore potential strategic alternatives that could provide greater value creation opportunities than QIAGEN’s already strong stand-alone growth prospects. This process was announced in mid-November after QIAGEN received several conditional, non-binding indications of interest for a full acquisition.

On December 24, 2019, the Supervisory Board and Management Board determined that the various alternatives to the stand-alone prospects were not compelling, and has terminated all discussions so that full management focus can be on executing the stand-alone plan.

“The Supervisory Board and Management Board conducted a wide-ranging review of strategic alternatives for our business and determined that the ongoing transformation provides the best means for creating future value for shareholders and other stakeholders,” said Dr. Håkan Björklund, Chairman of the Supervisory Board of QIAGEN N.V. “We have a strong and differentiated portfolio of molecular testing solutions that provide opportunity for significant growth. We will continue to focus on value-enhancing activities with financial discipline and an increased passion to serve our customers with our Sample to Insight solutions focused on the Life Sciences and Molecular Diagnostics.”

https://www.bionity.com/en/news/1164280/qiagen-concludes-strategic-alternatives-review.html